Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry

Redder, Louise; Klausen, Tobias W.; Vangsted, Annette Juul; Gregersen, Henrik; Andersen, Niels Frost; Pedersen, Robert S.; Szabo, Agoston Gyula; Frederiksen, Mikael; Frølund, Ulf Christian; Helleberg, Carsten; Nielsen, Lene Kongsgaard; Pedersen, Per Trøllund; Salomo, Morten; Gimsing, Peter; Frederiksen, Henrik; Abildgaard, Niels

doi:10.1111/bjh.16806

Cited by 13 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, they showed consistent results in terms of the prognostic value of MRP score; that is, the high-risk group had a higher risk of early death and a shorter PFS. 6 They also found that the high-risk group had much higher Cr, lower Hb, and higher LDH levels, which differed from the results of our study. 6 In addition, patients in the high-risk group had shorter treatment durations and worse treatment responses.…”

Section: Discussioncontrasting

confidence: 99%

“… 6 They also found that the high-risk group had much higher Cr, lower Hb, and higher LDH levels, which differed from the results of our study. 6 In addition, patients in the high-risk group had shorter treatment durations and worse treatment responses. 6 …”

Section: Discussioncontrasting

confidence: 99%

“… 6 In addition, patients in the high-risk group had shorter treatment durations and worse treatment responses. 6 …”

Section: Discussionmentioning

confidence: 99%

“…Individuals with a score of < −0.256 were classified as the low-risk group, while those with a score of −0.256 ≤ score ≤ −0.0283 and > −0.0283 were classified as the medium-risk group and high-risk group respectively. 6 …”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation

Ma¹,

Ye²,

Wang³

et al. 2021

OTT

View full text Add to dashboard Cite

Purpose Recently, the British Myeloma Research Alliance put forward a Myeloma Risk Profile (MRP) for the first time to stratify the prognosis risk of non-transplanted patients with multiple myeloma. However, only limited studies have evaluated the applicability of this model in the Chinese population. This study aimed to estimate the prognostic value of MRP in newly diagnosed multiple myeloma patients without autologous stem cell transplantation in China. Patients and Methods Patients with multiple myeloma in Wuxi People’s Hospital from January 1, 2007, to June 30, 2018 were evaluated based on the MRP score, and the relationship between the clinical outcome of patients with MM and the score was analyzed retrospectively. Results First, significant differences were observed in the overall survival (OS) (P<0.05) and progression-free survival (PFS) (P<0.05) between the low-, middle-, and high-risk groups. Second, in the bortezomib treatment subgroup and complex chromosome karyotype subgroup, OS and PFS were significantly shorter in the high-risk group than in the low-risk group (P<0.05). Third, the depth of remission still showed prognostic significance in the high-risk MRP group. Conclusion MRP is also applicable in Chinese patients with newly diagnosed MM who did not undergo transplantation, as it is simple and cost effective; hence, it is worth popularizing.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussioncontrasting

confidence: 99%

“… 6 In addition, patients in the high-risk group had shorter treatment durations and worse treatment responses. 6 …”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation

Ma¹,

Ye²,

Wang³

et al. 2021

OTT

View full text Add to dashboard Cite

show abstract

“…The risk profile defined by this score included both tumor characteristics (ISS stage) and host characteristics (performance status, age, CRP). The MRP score was retrospectively validated in real-life patients and will be prospectively validated and compared with the IMWG Frailty Score in the ongoing UK-MRA Myeloma XIV study (FiTNEss) [42].…”

Section: Abbreviations Who World Health Organization; Iss Internatmentioning

confidence: 99%

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients

Bonello

Boccadoro

Larocca

2020

Cancers

View full text Add to dashboard Cite

Multiple myeloma (MM) mostly affects elderly patients, which represent a highly heterogeneous population. Indeed, comorbidities, frailty status and functional reserve may vary considerably among patients with similar chronological age. For this reason, the choice of treatment goals and intensity is particularly challenging in elderly patients, and it requires a multidimensional evaluation of the patients and the disease. In recent years, different tools to detect patient frailty have been developed, and the International Myeloma Working Group frailty score currently represents the gold standard. It identifies intermediate-fit and frail patients requiring gentler treatment approaches compared to fit patients, aiming to preserve quality of life and prevent toxicities. This subset of patients is underrepresented in clinical trials, and studies exploring frailty-adapted approaches are scarce, making the choice of therapy extremely challenging. Treatment options for intermediate-fit and frail patients might include dose-adapted combinations, doublets, and less toxic combinations based on novel agents. This review analyzes the available tools for the assessment of frailty and possible strategies to improve the discriminative power of the scores and expand their use in real-life and clinical trial settings. Moreover, it addresses the main therapeutic challenges in the management of intermediate-fit and frail MM patients at diagnosis and at relapse.

show abstract

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

Højholt

Gregersen

Szabo

et al. 2021

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

Real world evidence is important since most patients cannot be included in randomized clinical trials (RCTs). In a nationwide, cohort of relapsed/refractory multiple myeloma patients treated with daratumumab (N = 635), we retrospective studied patients treated with carfilzomib (N = 251). Data were collected by audit of medical records. We compared characteristics of patients treated with carfilzomib before daratumumab (Car-Da; N = 150) and after daratumumab (Da-Car; N = 101) with those not treated with carfilzomib (N = 384). Furthermore, we examined effectiveness and safety of carfilzomib. The group of patients treated with carfilzomib differed from patients not treated with carfilzomib in the following parameters: They were younger, more were treated up-front with high dose melphalan and

show abstract

Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry

Cited by 13 publications

References 13 publications

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

Contact Info

Product

Resources

About